NfL, tau, NSE and S100B have repeatedly been reported useful as circulating biomarkers of cerebral injury in other neurological disorders such as neurodegenerative disease, traumatic brain injury and epilepsy [8,9,10,14,15,39]. This evidence concerns the gene MAPT and neurodegenerative disease.